siRNA therapeutics for effective management of rheumatoid arthritis

Vishakha R. Chakole , Tathagata Dutta , Priyankar Sen
{"title":"siRNA therapeutics for effective management of rheumatoid arthritis","authors":"Vishakha R. Chakole ,&nbsp;Tathagata Dutta ,&nbsp;Priyankar Sen","doi":"10.1016/j.nxnano.2025.100135","DOIUrl":null,"url":null,"abstract":"<div><div>siRNA is a specialized type of RNA that precisely targets a mRNA, and effectively silences the respective genes. This property makes siRNA a valuable tool for developing RNAi therapeutics, particularly for managing conditions like osteoporosis, cancer, genetic disorders, and autoimmune disorders. Rheumatoid arthritis (RA) is a significant autoimmune disorder. Several treatments are available for RA, including analgesics, corticosteroids, DMARDs, biological agents, combinational therapy, epigenetic and cell therapies which play a crucial role in preventing joint function deterioration, inflammation, synovial edema, etc. Besides these numerous advantages, these treatments have several disadvantages like liver cirrhosis, interstitial lung disease, sexual health is impaired in males, neuropsychiatric adverse effects, etc. All these disadvantages engender the need for new therapy. siRNA delivery carriers like liposomes, polymeric nanoparticles, and siRNA polymer bio-conjugates are proving to be particularly effective with less toxicity compared to the traditional treatments. A promising addition to these carriers is wrapsome (WS), which can be used as a favorable carrier for delivery of siRNA to its specific sites, such as inflamed joints or the inflamed synovium. The incorporation of PEG liposomes in the delivery strategy allows WS to evade recognition by the RES, leading to an extended half-life. This extended half-life enables a sustained, slow release of the drug, contributing to superior recovery from pain and inflammation associated with conditions like RA.</div></div>","PeriodicalId":100959,"journal":{"name":"Next Nanotechnology","volume":"7 ","pages":"Article 100135"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Next Nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S294982952500004X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

siRNA is a specialized type of RNA that precisely targets a mRNA, and effectively silences the respective genes. This property makes siRNA a valuable tool for developing RNAi therapeutics, particularly for managing conditions like osteoporosis, cancer, genetic disorders, and autoimmune disorders. Rheumatoid arthritis (RA) is a significant autoimmune disorder. Several treatments are available for RA, including analgesics, corticosteroids, DMARDs, biological agents, combinational therapy, epigenetic and cell therapies which play a crucial role in preventing joint function deterioration, inflammation, synovial edema, etc. Besides these numerous advantages, these treatments have several disadvantages like liver cirrhosis, interstitial lung disease, sexual health is impaired in males, neuropsychiatric adverse effects, etc. All these disadvantages engender the need for new therapy. siRNA delivery carriers like liposomes, polymeric nanoparticles, and siRNA polymer bio-conjugates are proving to be particularly effective with less toxicity compared to the traditional treatments. A promising addition to these carriers is wrapsome (WS), which can be used as a favorable carrier for delivery of siRNA to its specific sites, such as inflamed joints or the inflamed synovium. The incorporation of PEG liposomes in the delivery strategy allows WS to evade recognition by the RES, leading to an extended half-life. This extended half-life enables a sustained, slow release of the drug, contributing to superior recovery from pain and inflammation associated with conditions like RA.
类风湿性关节炎有效治疗的siRNA疗法
siRNA是一种特殊类型的RNA,它精确地靶向mRNA,并有效地沉默相应的基因。这一特性使siRNA成为开发RNAi疗法的宝贵工具,特别是在治疗骨质疏松症、癌症、遗传疾病和自身免疫性疾病等疾病方面。类风湿性关节炎(RA)是一种重要的自身免疫性疾病。风湿性关节炎有几种治疗方法,包括镇痛药、皮质类固醇、dmard、生物制剂、联合治疗、表观遗传和细胞治疗,它们在预防关节功能恶化、炎症、滑膜水肿等方面起着至关重要的作用。除了这些优点之外,这些治疗方法也有一些缺点,如肝硬化、间质性肺病、男性性健康受损、神经精神不良反应等。所有这些缺点都需要新的治疗方法。与传统治疗方法相比,siRNA递送载体如脂质体、聚合物纳米颗粒和siRNA聚合物生物偶联物被证明特别有效,毒性更小。除了这些载体外,包裹体(wrapsome, WS)是一种很有前景的载体,它可以作为一种有利的载体,将siRNA运送到其特定部位,如发炎的关节或发炎的滑膜。PEG脂质体在递送策略中的结合允许WS逃避RES的识别,导致半衰期延长。这种延长的半衰期使药物能够持续缓慢释放,有助于从与类风湿性关节炎相关的疼痛和炎症中获得更好的恢复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信